Compare · IRWD vs JNJ
IRWD vs JNJ
Side-by-side comparison of Ironwood Pharmaceuticals Inc. (IRWD) and Johnson & Johnson (JNJ): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both IRWD and JNJ operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- JNJ is the larger of the two at $609.12B, about 958.6x IRWD ($635.4M).
- Over the past year, IRWD is up 397.7% and JNJ is up 54.6% - IRWD leads by 343.2 points.
- JNJ has been more active in the news (10 items in the past 4 weeks vs 2 for IRWD).
- JNJ has more recent analyst coverage (25 ratings vs 14 for IRWD).
- Company
- Ironwood Pharmaceuticals Inc.
- Johnson & Johnson
- Price
- $3.85-0.77%
- $253.01+1.39%
- Market cap
- $635.4M
- $609.12B
- 1M return
- +4.90%
- +7.55%
- 1Y return
- +397.74%
- +54.56%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2010
- News (4w)
- 2
- 10
- Recent ratings
- 14
- 25
Ironwood Pharmaceuticals Inc.
Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and Mexico, as well as under the CONSTELLA name in the Canada and European Union. The company is also developing IW-3300, a GC-C agonist, which is in pre-clinical development for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis. It has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.
Johnson & Johnson
Johnson & Johnson researches and develops, manufactures, and sells a range of products in the health care field worldwide. It operates through three segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; smoking cessation products under the NICORETTE brand; and acid reflux products under the PEPCID brand. This segment also provides women's health products, such as sanitary pads and tampons under the STAYFREE, CAREFREE, and o.b. brands; wound care products comprising adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. The Pharmaceutical segment offers products in various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular and metabolic diseases. The Medical Devices segment provides electrophysiology products to treat cardiovascular diseases and neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery under the ACUVUE brand. The company markets its products to general public, and retail outlets and distributors, as well as distributes directly to wholesalers, hospitals, and health care professionals for prescription use. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.
Latest IRWD
- Ironwood Appoints Dr. Jeffrey Silber Chief Medical Officer and Head of Research and Drug Development; STARS-2 Trial Initiated in June and Is Now Actively Recruiting Patients
- PFO & PAO Silver Ronald sold $578,063 worth of shares (127,890 units at $4.52) as part of a pre-agreed trading plan, decreasing direct ownership by 29% to 313,680 units (SEC Form 4)
- Ironwood Pharmaceuticals Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits
- Director Shepard Jay was granted 63,481 shares, increasing direct ownership by 37% to 235,036 units (SEC Form 4)
- Director Kessler Marla L was granted 63,481 shares, increasing direct ownership by 38% to 229,364 units (SEC Form 4)
- Director Currie Mark G was granted 63,481 shares, increasing direct ownership by 10% to 676,900 units (SEC Form 4)
- Director Duane Jon R was granted 63,481 shares, increasing direct ownership by 33% to 253,820 units (SEC Form 4)
- Director Denner Alexander J was granted 67,546 shares, increasing direct ownership by 26% to 323,855 units (SEC Form 4)
- Director Mchugh Julie sold $80,460 worth of shares (21,571 units at $3.73) as part of a pre-agreed trading plan and was granted 63,481 shares, increasing direct ownership by 20% to 250,749 units (SEC Form 4)
- Director Moukheibir Catherine was granted 63,481 shares, increasing direct ownership by 54% to 181,425 units (SEC Form 4)
Latest JNJ
- Johnson & Johnson Announces Collaboration with TIME to Introduce New Healthcare Champion of the Year Award
- DePuy Synthes Acquires Expanding Innovations™
- Johnson & Johnson filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Johnson & Johnson Announces Quarterly Dividend for Third Quarter 2026
- Johnson & Johnson reports Q2 2026 results, raises 2026 outlook
- Johnson & Johnson Announces FDA Approval for the Dual Energy THERMOCOOL SMARTTOUCH SF Platform
- Multi-Billion-Dollar Battle for the Future of Depression Treatment Has Begun Creating a Huge Opportunity
- Johnson & Johnson presents new IMAAVY® (nipocalimab-aahu) data at European Academy of Neurology (EAN) 2026 Congress reinforcing sustained disease control in generalized myasthenia gravis
- SEC Form 11-K filed by Johnson & Johnson
- SEC Form 11-K filed by Johnson & Johnson